SCHEMBL6327638

SCHEMBL6327638

Cc1[nH]c(/C=C2\C(=O)Nc3cccc(-c4ccc(Cl)cc4)c32)c(C)c1C(=O)N1CCC(N2CCCC2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 13/20 0.45
FGFR1 P11362 7/20 0.45
MET P08581 5/20 0.45
MEN1 O00255 2/20 0.45
CDK2 P24941 2/20 0.45
KMT2A Q03164 2/20 0.45
PTK2B Q14289 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
CCNE1 P24864 1/20 0.45
RECQL P46063 1/20 0.45
FLT1 P17948 1/20 0.45
PDGFRB P09619 8/20 0.42
FLT3 P36888 3/20 0.42
KIT P10721 3/20 0.42
EGFR P00533 3/20 0.42
PRKAA2 P54646 3/20 0.42
PRKAA1 Q13131 3/20 0.42
ABL1 P00519 2/20 0.42
RET P07949 2/20 0.42
ALK Q9UM73 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6319780 0.92 KDR (0.49) KDRFGFR1METMEN1CDK2
SCHEMBL6321444 0.90 KDR (0.46) KDRFGFR1METMEN1CDK2
SCHEMBL6324286 0.89 KDR (0.46) KDRFGFR1METMEN1CDK2
SCHEMBL6323810 0.88 KDR (0.53) KDRFGFR1METMEN1CDK2
SCHEMBL6323103 0.88 KDR (0.49) KDRFGFR1METMEN1CDK2
SCHEMBL6320750 0.87 KDR (0.57) KDRFGFR1METMEN1CDK2
SCHEMBL6320753 0.87 KDR (0.57) KDRFGFR1METMEN1CDK2
SCHEMBL6322137 0.87 KDR (0.43) KDRFGFR1METMEN1CDK2
SCHEMBL6320446 0.87 KDR (0.44) KDRFGFR1METMEN1CDK2
SCHEMBL6320434 0.86 KDR (0.48) KDRFGFR1METMEN1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885FGFR1 525/4885MET 501/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885FGFR1 525/4885MET 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.